Factory Mutual Insurance Co. Sells 23,700 Shares of DexCom, Inc. $DXCM

Factory Mutual Insurance Co. lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 4.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 497,930 shares of the medical device company’s stock after selling 23,700 shares during the period. Factory Mutual Insurance Co.’s holdings in DexCom were worth $43,464,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in DXCM. Vanguard Group Inc. increased its stake in shares of DexCom by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock worth $3,240,763,000 after purchasing an additional 925,882 shares during the last quarter. Jennison Associates LLC boosted its holdings in DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after purchasing an additional 994,300 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after buying an additional 1,868,241 shares during the last quarter. Nuveen LLC acquired a new stake in shares of DexCom in the first quarter worth about $554,893,000. Finally, Raymond James Financial Inc. boosted its stake in shares of DexCom by 21.8% during the 1st quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock worth $229,117,000 after acquiring an additional 601,088 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Alexander Collins sold 3,948 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $55.17, for a total value of $217,811.16. Following the sale, the director owned 37,994 shares in the company, valued at approximately $2,096,128.98. This represents a 9.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 9,331 shares of company stock valued at $652,085 over the last quarter. Company insiders own 0.32% of the company’s stock.

DexCom Trading Down 0.3%

Shares of DXCM stock opened at $54.84 on Tuesday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $93.25. The firm’s fifty day simple moving average is $68.83 and its 200 day simple moving average is $77.61. The firm has a market capitalization of $21.39 billion, a P/E ratio of 38.08, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent analyst reports. Raymond James Financial raised their price objective on DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 31st. TD Cowen reduced their price objective on shares of DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Royal Bank Of Canada decreased their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Stifel Nicolaus initiated coverage on shares of DexCom in a report on Tuesday, October 21st. They issued a “buy” rating and a $85.00 target price on the stock. Finally, Sanford C. Bernstein reissued an “outperform” rating and set a $84.00 target price on shares of DexCom in a research report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $87.62.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.